Frazier Life Sciences Management, L.P. Merus N.V. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Merus N.V. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 373,100 shares of MRUS stock, worth $18.5 Million. This represents 1.0% of its overall portfolio holdings.
Number of Shares
373,100
Previous 373,100
-0.0%
Holding current value
$18.5 Million
Previous $22.1 Million
15.56%
% of portfolio
1.0%
Previous 1.3%
Shares
4 transactions
Others Institutions Holding MRUS
# of Institutions
197Shares Held
62MCall Options Held
124KPut Options Held
208K-
Rtw Investments, LP New York, NY4.17MShares$207 Million3.32% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.41MShares$169 Million3.17% of portfolio
-
Commodore Capital LP New York, NY3.35MShares$166 Million14.22% of portfolio
-
Wellington Management Group LLP Boston, MA2.89MShares$143 Million0.03% of portfolio
-
Samlyn Capital, LLC New York, NY2.61MShares$130 Million2.1% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.28B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...